Key result
Pimobendan administration was associated with a significantly longer median survival time (626 days) compared to treatment without pimobendan (103 days) in cats with CHF secondary to HCM or HOCM.
Why the study?
Does pimobendan improve survival time in cats with congestive heart failure secondary to hypertrophic cardiomyopathy?
Case-Control (n=54)
Does pimobendan improve survival time in cats with congestive heart failure secondary to hypertrophic cardiomyopathy?
Absolute Event Rate: 626% vs 103%
The addition of pimobendan to traditional treatment for CHF provides a substantial survival benefit in cats with HCM or HOCM.
Authors
No takes yet. Share an insight, caveat, or question.
May support pimobendan in cats with HCM-related CHF; hypothesis-generating and requires randomized trials before practice change.
Reina‐Doreste et al. (2014) conducted a case-control in Congestive heart failure secondary to hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy (n=54). Pimobendan vs. Treatment without pimobendan was evaluated on Survival time. Pimobendan administration was associated with a significantly longer median survival time (626 days) compared to treatment without pimobendan (103 days) in cats with CHF secondary to HCM or HOCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: